Evaluation and management of abnormal liver enzymes in the liver transplant recipient: When, why, and what now? [0.03%]
肝移植受者的异常肝脏酶的评估和管理：何时、为何以及下一步如何进行？
Emily Harding-Theobald,Michael Kriss
Emily Harding-Theobald
Armando Bosch,Kimberly E Daniel
Armando Bosch
Obesity management for the pre-liver transplant and post-liver transplant patient [0.03%]
肝移植前后的肥胖症管理
Carolyn Ahlers,Matthew Kappus
Carolyn Ahlers
Evaluation and management of post-transplant infections for the hepatologist [0.03%]
肝病学家的移植后感染评估与管理
Omobonike Oloruntoba-Sanders,Sajal D Tanna
Omobonike Oloruntoba-Sanders
A practical approach to extrahepatic cancer screening before and after liver transplant [0.03%]
肝移植前后体外癌症筛查的实际方法
Rahul Mohan,Jonathan Rice
Rahul Mohan
Culture, stigma, and inequities creating barriers in alcohol use disorder management in alcohol-associated liver disease [0.03%]
文化、污名和不平等造成的障碍，阻碍酒精使用障碍在与酒精相关肝病管理中的治疗
Mary Sedarous,Jennifer A Flemming
Mary Sedarous
Rise in alanine aminotransferase after HCV treatment is a highly sensitive screen for treatment failure [0.03%]
丙肝治疗后丙氨酸氨基转移酶升高可高度提示治疗失败
Barnaby Flower,Phuong Nguyen Thi Ngoc,Leanne McCabe et al.
Barnaby Flower et al.
Nucleic acid testing to confirm sustained virological response (SVR) after HCV therapy is technical, often expensive, and frequently unavailable where disease prevalence is highest. Alternative surrogate biomarkers merit evaluation. In a sh...
Gerald Scott Winder,Erin G Clifton
Gerald Scott Winder
What guidelines?: Attitudes and behaviors for prescribing prophylactic hepatic encephalopathy medications [0.03%]
何规范：预防性使用肝性脑病药物的处方态度和行为
Chip A Bowman,Joyce Zhang,Lauren T Grinspan
Chip A Bowman
The current landscape of pediatric living donor liver transplantation in the United States: Benefits, challenges, and future directions [0.03%]
美国儿童活体肝移植的现状：好处、挑战和未来方向
Dor Yoeli,Megan A Adams,Elizabeth A Pomfret
Dor Yoeli